Identifying potential indicators to measure the outcome of translational cancer research: a mixed methods approach by Thonon, Frédérique et al.
Identifying potential indicators to measure the outcome
of translational cancer research: a mixed methods
approach
Fre´de´rique Thonon, Rym Boulkedid, Maria Teixeira, Serge Gottot, Mahasti
Saghatchian, Corinne Alberti
To cite this version:
Fre´de´rique Thonon, Rym Boulkedid, Maria Teixeira, Serge Gottot, Mahasti Saghatchian,
et al.. Identifying potential indicators to measure the outcome of translational cancer re-
search: a mixed methods approach. Health Research Policy and Systems, 2015, 13 (1), pp.72.
<10.1186/s12961-015-0060-5>. <inserm-01264505>
HAL Id: inserm-01264505
http://www.hal.inserm.fr/inserm-01264505
Submitted on 29 Jan 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH Open Access
Identifying potential indicators to measure
the outcome of translational cancer
research: a mixed methods approach
Frédérique Thonon1,2,3,4* , Rym Boulkedid2,3,4, Maria Teixeira2, Serge Gottot2,3,4, Mahasti Saghatchian1†
and Corinne Alberti2,3,4†
Abstract
Background: In a context where there is an increasing demand to evaluate the outcome of bio-medical research,
our work aims to develop a set of indicators to measure the impact of translational cancer research. The objective
of our study was to explore the scope and issues of translational research relevant to evaluation, explore the views
of researchers on the evaluation of oncological translational research, and select indicators measuring the outcomes
and outputs of translational research in oncology by consensus.
Methods: Semi-structured interviews amongst 23 researchers involved in translational cancer research were
conducted and analysed using thematic analysis. A two-round modified Delphi survey of 35 participants with
similar characteristics was then performed followed by a physical meeting. Participants rated the feasibility and
validity of 60 indicators. The physical meeting was held to discuss the methodology of the new indicators.
Results: The main themes emerging from the interviews included a common definition for translational research
but disagreements about the exact scope and limits of this research, the importance of multidisciplinarity and
collaboration for the success of translational research, the disadvantages that translational research faces in current
evaluation systems, the relative lack of pertinence of existing indicators, and propositions to measure translational
cancer research in terms of clinical applications and patient outcomes. A total of 35 participants took part in the
first round survey and 12 in the second round. The two-round survey helped us select a set of 18 indicators,
including four that seemed to be particularly adapted to measure translational cancer research impact on health
service research (number of biomarkers identified, generation of clinical guidelines, citation of research in clinical
guidelines, and citation of research in public health guidelines). The feedback from participants helped refine the
methodology and definition of indicators not commonly used.
Conclusion: Indicators need to be accepted by stakeholders under evaluation. This study helped the selection and
refinement of indicators considered as the most relevant by researchers in translational cancer research. The
feasibility and validity of those indicators will be tested in a scientometric study.
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Background
Measuring the long-term impact of translational cancer
research, particularly that on health service and patient
outcomes, has become of crucial importance. The con-
cept of translational research has been described by Elias
Zerhouni, the former director of the National Institute
of Health, as “crossing the valley of death” between bio-
medical research and clinical applications [1], and has
been formally defined as “research that transforms scien-
tific discoveries arising in the lab, clinic, or population
into new clinical tools and applications that reduce can-
cer incidence, morbidity, and mortality” [2]. While this
type of research, focused on improving patient out-
comes, has increasingly become the centre of attention
[3], there has meanwhile been an increase in the demand
to measure the outcome of biomedical research in terms
of patient benefits and move beyond classical bibliomet-
ric indicators [4]. Many professional bodies have devel-
oped indicators for various fields, with the goals of
improving quality by detecting suboptimal performance
based on the traditional Donabedian model, which as-
sesses structures, processes and outcomes [5]. According
to Pozen et al. [6], indicators can help track a transla-
tional research organisation’s progress towards goals, as
well as highlight achievements and identify areas for
improvement.
Our work is part of a broad initiative to assess the
quality of translational oncological research. Other re-
searchers have focused on developing an assessment
framework, called the Excellence Designation System,
containing 18 criteria to identify excellent comprehen-
sive cancer centres [7]. We aim to develop metrics to
measure the outcome and impact of translational cancer
research. In this article, we make a distinction between
output and outcome indicators. We define output as
“the immediate tangible result of an activity” and out-
comes as “longer term effects such as impact on
health” [8]. Impact is defined as “the overall results of
all the effects of a body of research have on society.
Impact includes outputs and outcomes, and may in-
clude additional contributions to the health sector or
society” [9].
We first performed a systematic review of indicators
measuring the outcome of biomedical research, includ-
ing their methodology, use, and positive and negative
points [10]. We found a total of 57 indicators classified
into six categories: indicators of scientific production
and impact, indicators of collaboration, indicators of
industrial production, indicators of dissemination, and
indicators of health service impact. The vast majority
of indicators found were bibliometric indicators meas-
uring scientific production and impact. Given the im-
portant number of indicators retrieved, it is now
necessary to select the ones that are the most
relevant to evaluate the outcome of translational can-
cer research.
The OECD states three criteria to select indicators,
namely the importance of what is being measured, its
scientific soundness, and its validity [11]. The import-
ance of what is being measured refers mainly to its pol-
icy importance. The scientific soundness of an indicator
includes its validity (the capacity of an indicator to
measure what it is intended to measure), reliability (its
capacity to provide stable results when repeated by
different people), and explicitness of the scientific base
(scientific evidence to support the use of the indicator).
The feasibility of an indicator includes characteristics
such as existence of prototype (whether the indicator is
already in place), the availability of data source, and the
cost and burden of measuring that indicator [11].
The aim of our study was to define a set of indicators
to measure the output and outcome of oncological
translational research. Specifically, we wanted to explore
the scope and issues of translational research relevant to
evaluation and the views of researchers on the evalu-
ation of oncological translational research, and to select
indicators measuring the outcomes and outputs of trans-
lational research in oncology by consensus.
Methods
Study design
This study was undertaken as part of a project aiming to
develop and test indicators measuring the outcome of
translational cancer research. We used several steps to
develop and select indicators measuring the outcome of
translational research (Figure 1) starting with a system-
atic literature review whose results are reported in a pre-
vious article [10]. We used a mixed-methods approach
in order to select a set of indicators to measure the out-
put and outcome of oncological translational research. A
mixed-methods design is defined as a design that
includes at least one quantitative method (collecting
numbers) and one qualitative method (collecting words)
[12]. As such, the present study involves semi-structured
interviews followed by a modified Delphi survey
amongst researchers. The Delphi technique is a struc-
tured process that uses a series of questionnaires to
gather information. Rounds are held until group consen-
sus is reached. A modified Delphi survey is composed of
at least two rounds and a physical meeting [13].
Participants
For the qualitative study, we invited professionals
(clinicians, engineers, researchers, administrative staff )
working in translational cancer research. Since transla-
tional cancer research involves many different disciplines
and professionals, we did not select participants accord-
ing to their qualification but only according to their
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involvement in translational cancer research. We defined
involvement in translational cancer research as either of
the following:
– Working in a research department or unit clearly
identified as a conducting translational oncological
research (e.g. translational research platform of a
cancer hospital)
– Involved in a consortium clearly identified as a
translational cancer research consortium (e.g.
EurocanPlatform or ERA-NET on translational
cancer research)
– Having presented their work in a translational
cancer research conference (e.g. the ‘translational
research’ session of the European Society for
Medical Oncology or American Society of Clinical
Oncology conference)
– Teaching in a course or training on translational
research in oncology
In addition, we used the ‘snowballing’ method, asking
participants to recommend other participants involved
in translational cancer research. To form a diverse
sample, we sought to include a wide range of professions
and practice disciplines and backgrounds in order to
ensure that they will represent all potential differences
in background, occupational environment, clinical ap-
proaches, or practices. We included participants until
the saturation point was reached, i.e. until additional in-
terviews produced no new information. In this type of
interviews, the saturation point is usually reached after
20 interviews [14].
For the Delphi survey, we invited all participants of the
EurocanPlatform network (n = 267). EurocanPlatform is a
consortium of 28 cancer organisations (cancer centres and
cancer research institutions) in Europe dedicated to trans-
lational research on cancer prevention, early detection
and treatment. Differences in the recruitment strategies
between the qualitative study and the Delphi survey are
explained by the different constraints and objectives of
each study. For the qualitative study, we favoured partici-
pants with a close geographical location in order to allow
face-to-face rather than phone interviews so as to obtain
more in-depth information. For the Delphi survey, we re-
stricted participation to staff from our consortium in
order to receive a more specific feedback.
Figure 1 Indicator development and selection process.
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Interviews
We conducted semi-structured interviews (with open
questions) of professionals involved in translational
oncological research around three key themes: (1) defin-
ition and scope of translational research, (2) issues and
objectives of translational research, and (3) evaluation of
the outcome of translational research. The interview
guide was designed by FT, MT and SG and tested
amongst four participants meeting the inclusion criteria
mentioned above. The study objective was briefly pre-
sented to the participants at the beginning of the inter-
views. Two of those pilot interviews were kept in the
final set. As two participants were interviewed con-
jointly, we conducted 22 interviews face-to-face (n = 18)
or by telephone (n = 4) and audio-recorded them. Inter-
views lasted between 15 and 52 minutes, with an average
of 25 minutes. All interviews were fully transcripted ver-
batim. We used a thematic analysis for our study with
the help of NVivo10 software. According to a method
proposed by Burnard to increase the validity of findings
[15], FT, RB, MT and SG studied a sample of five inter-
view transcripts to identify emerging themes, and then
the recurring ones. Those themes were then applied as
‘codes’ used to code interviews. We report the results of
this analysis according to the Consolidated Criteria for
Reporting Qualitative research (COREQ) guidelines [16]
(Additional file 1).
Survey
We conducted a modified Delphi survey [13] amongst
researchers in translational cancer research. We invited
267 members of the project to participate in the survey.
Participants were sent the online questionnaire by email,
with a reminder email in case of non-response. Partici-
pants were presented an initial list of indicators com-
posed of all indicators retrieved from the systematic
review of the literature [10] and suggested by researchers
in the qualitative study, with the definition and positive
and negative points according to the literature. No filter
on feasibility or validity was used to pre-select indicators
from the initial list. The initial list submitted to partici-
pants included a mix of ‘traditional’ indicators measur-
ing research dissemination and other indicators
measuring alternative ways to disseminate research re-
sults, such as ‘citation of research in clinical guidelines’,
‘citation of research in public health guidelines’, ‘report-
ing of research in the news/media’ and ‘citation in med-
ical education books’. The questionnaire was previously
tested amongst two researchers. Each participant was in-
vited to rate the indicators based on validity and feasibil-
ity on a scale of 1–9 (1 for indicators definitely not
feasible or valid and 9 for indicators definitely feasible or
valid). Each participant was also invited to comment on
each indicators using a dedicated ‘comment box’, and/or
to suggest indicators considered as important. Partici-
pants’ characteristics were noted, including their work-
place, number of years of experience and training. The
entire questionnaire can be found in Additional file 2.
The definition of a ‘consensus’ among participants in a
Delphi survey is not agreed upon, and various definitions
have been previously used. We chose to apply the defin-
ition used by Shield et al. [17]. The median was used to
measure the central tendency for the ratings. The final
disposition of each indicator was based on the median
validity rating, median feasibility rating, and agreement
among panellists expressed as a percentage. A higher
agreement rate was required in the second than in the
first round, as second-round participants were aware of
the survey contents and received feedback about the first
round, including the median ratings with the ranges, the
participants’ responses, and a summary of all the com-
ments received. These data allowed each participant to
assess their position relative to the rest of the group,
which may have influenced the response to the second
round.
In the first round, we selected indicators for which a
consensus was achieved regarding validity and feasibility,
i.e. for which the median score was in the top tertile
(7–9) and at least 65% of panel ratings were in the
top tertile. To be included in the final set, indicators
had to have median validity and feasibility ratings in
the top tertile (7–9) and 75% agreement among
panellists that the rating was in the top tertile. We
excluded all other indicators, except those that re-
ceived significant questions or comments suggesting a
change in definition or methodology, which we sub-
mitted to the second round with the proposed modi-
fications or clarifications.
On the second round, the questionnaire was persona-
lised for each respondent. Participants received an indi-
vidualised survey form by email presenting their rating,
as well as the average rating and comments for each
indicator. They were given the opportunity to re-rate
in light of those new elements. For the second round,
we asked participants to rate only the validity of the
indicators (and not the feasibility) in order to make
the questionnaire less burdensome and allow more
in-depth feedback on indicators. Each round was car-
ried out over a 2-month period (February–March and
May–June 2014).
To refine the indicator development and selection
process, we held a physical meeting of participants to
discuss indicators for which there was debate on the
methodology or calculation.
Ethics statement
The qualitative study and the Delphi survey did not in-
volve patients and written consent was not required. We
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ensured confidentiality for all participants. We described
the study objective and confidentiality treatment before
the start of each interview and at the beginning of the
survey, and subsequently requested the participant’s con-
sent for audio recording. We anonymised all data linked
to participants in the final data set.
Results
Characteristics of participants
Participants in the qualitative study
We invited 31 actors of translational research in oncol-
ogy to take part in our study, eight of whom refused due
to time constraints or did not reply. A total of 23 re-
searchers, engineers, clinicians or administrators were fi-
nally included, amongst them seven women and 16 men.
We reached the saturation point after 23 participants.
The number of years they worked in cancer research
ranged from 5 to 37 years, with a median of 19 years.
We interviewed a mix of medical doctors (n = 10), phar-
macists (n = 6) and scientists (n = 7), holding degrees in
disciplines as diverse as physics, biology and chemistry.
The characteristics of participants are shown in Table 1.
Participants in the modified Delphi survey
Of the 267 participants invited to complete the survey,
35 participated in the first round, of whom 69% were
men (n = 24) and 31% women (n = 11). Most of the par-
ticipants had a degree either in medicine (n = 21) or/and
biology (n = 13). The number of years they worked in
cancer research ranged from 4 to 40 years, with a median
of 25 years. The participants were affiliated to 21 different
institutions out of the 28 of the consortium. The charac-
teristics of participants are described in Table 1.
Two researchers participated in both the qualitative
study and Delphi survey (one clinician-researcher and
one biologist). One pharmacist participated in the pilot
of the qualitative study and the Delphi survey.
Themes and subthemes extracted from the qualitative
study
We extracted themes and sub-themes from the interviews.
The main themes from the interviews were (1) definition
of translational research; (2) the organization of transla-
tional cancer research; (3) the importance of multidiscipli-
narity and collaboration for the success of translational
research; (4) the optimal conditions and barriers for con-
ducting translational research; and (5) issues related to the
evaluation of translational research.
Herein, we present the themes most relevant to our
study objectives and the selection of indicators, namely
definition of translational research, necessity of multidis-
ciplinarity and collaboration, and issues related to the
evaluation of translational research. We summarised and
grouped the themes ‘definition’ and ‘multidisciplinarity’
under the same sub-part ‘issues to consider when devel-
oping an evaluation system’ and presented the ‘issues
related to evaluation’ as a single sub-part because we
thought this last theme was of particular significance
and needed to be more detailed.
Issues to consider when developing an evaluation system
(qualitative study)
Definition of translational research: a common basis but
unclear limits and scope
The majority of participants of the qualitative study sub-
scribed to a ‘bench-to-bedside’ definition of translational
research, meaning a translation of basic findings into
clinical research. However, some discrepancies could be
observed in terms of what exactly was included in the
definition of translational research. Discrepancies were
found in the following areas: whether or not transla-
tional research is a two-way process (including bedside-
to-bench process) or a one-way process (restricted to
bench-to-bedside); whether translational research stops
at the translation to clinical research or if it includes
translation of research findings to clinical practice,
whether translational research includes pre-clinical re-
search on mouse models or whether it is restricted to re-
search on human subjects or samples, and whether or
not research in epidemiology or cancer prevention is
part of translational research.
The majority of participants described translational re-
search as the discipline transferring findings from basic
or fundamental science into clinical science without
spontaneously mentioning the second aim of transla-
tional research, which is to use clinical observation to
enrich fundamental research. Five researchers explicitly
stated the bi-directional characteristic of translational re-
search on the basis that the objectives of translational
research are both to better treat cancer patients and to
develop our understanding of cancer. Two researchers
rejected this bi-directional definition of translational re-
search. One of them mentioned:
“I tend to consider translational research in one way
only. From the lab to the clinic. It is true that there
might be some disciplines where the other way, from
the clinic to the lab, can also be done. But as I tend to
consider it one way only, I think we shouldn’t keep on
funding laboratories of so-called translational research
that don’t translate anything.” (Clinician-researcher,
university hospital, 21 years of experience in cancer
research)
While most participants mentioned translational re-
search as the translation from basic research to clinical
research, only two participants also mentioned the trans-
lation of research into clinical practice.
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There was also disagreement about whether or not
translational research was restricted to research carried
out in humans or if it included pre-clinical research such
as mouse models. While some participants explicitly
stated that translational research was restricted to the re-
search carried out in humans or human samples, others
identified their research as translational research, even if it
was not carried out on human samples or on patients. Fi-
nally, while most participants defined translational re-
search as having therapeutic aims, one participant insisted
on the inclusion of research into risk factors and epidemi-
ology as part of translational research.
It should also be noted that two participants rejected
the notion of translational research, as an ill-defined
concept. As one researcher mentioned:
“People put whatever they want [in the definition of
translational research] because it does not really mean
anything. It is a trendy word because every other year
we need a new fancy word. It used to be ‘transfer
research’ then ‘applied research’.” (Clinician-researcher,
university hospital, 37 years of experience in cancer
research)
Some researchers (n = 4) expressed concerns about a
lack of interest for some disciplines within the transla-
tional research continuum, namely imaging, radiother-
apy and epidemiology/prevention. One participant
mentioned the influence of industry and the donors’
desire to find a cure for cancer as reasons for the imbal-
ance between research in epidemiology/prevention and
therapeutic research:
“There is much more investment into clinical research
than in epidemiological and prevention research.
There are two reasons for that: the first is that the
public wants a cure to cancer. […] Charities funding
cancer research adapt their priorities to the requests of
donors. The second reason is financial. Epidemiological
research does not profit companies, although it saves the
government money. There should be a stronger public
support for epidemiological research, as clinical research
is already supported by industries. Charities and the
public should be more biased towards epidemiological
research.” (Researcher, public research institute,
26 years of experience in cancer research)
Table 1 Characteristics of participants in each survey
Qualitative
study n (%)
(n = 23)
Delphi first
round n (%)
(n = 35)
Years of experience in cancer research
5–9 7 (30) 5 (14)
10–14 2 (9) 4 (12)
15–19 5 (22) 4 (12)
20–24 2 (9) 11 (31)
25–29 5 (21) 6 (17)
≥30 2 (9) 5 (14)
Sex
Male 16 (70) 24 (69)
Female 7 (30) 11 (31)
Institution of affiliation type
Comprehensive cancer centre 11 (48) 17 (49)
University hospital 6 (26) 11 (31)
Public research institute (not affiliated to a
hospital or cancer centre)
2 (9) 4 (11)
National agency 2 (9) 0
International or European agency 2 (9) 0
Industry (pharmaceutical or consulting) 0 3 (9)
Country
French institution 18 (79) 3 (9)
Italian institution 1 (4) 8 (23)
Dutch institution 0 6 (17)
British institution 0 4 (11)
Belgian institution 0 3 (9)
Other European country institution 3 (13) 11 (31)
International institution 1 (4) 0
Training
Masters degree (MSc) 0 1 (3)
Medical degree (MD) 2 (9) 7 (20)
Medical degree and MSc 1 (4) 0
Medical degree and PhD 7 (30) 14 (40)
Pharmacy degree (PharmaD) 1 (4) 0
Pharmacy degree and PhD 5 (22) 1 (3)
PhD 7 (30) 12 (34)
PhD or MSc specialisation 20 28
Biology 10 (50) 13 (46)
Chemistry or biochemistry 2 (10) 2 (7)
Pharmacology 2 (10) 0
Physics 2 (10) 2 (7)
Computer sciences 1 (5) 0
Management of healthcare organisations 0 2 (7)
Immunology 1 (5) 2 (7)
Genetics 1 (5) 3 (10)
Table 1 Characteristics of participants in each survey
(Continued)
Epidemiology/statistics 0 2 (7)
Biotechnology 1 (5) 1 (4)
Pathology 0 1 (4)
Note: Two participants took part in both studies.
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Multidisciplinarity and collaboration are crucial for the
successful conduct of translational research
All participants mentioned the importance of collabor-
ation as an essential condition for translational research.
It was usually considered as the most important issue in
the conduct of translational research. In this context,
collaboration meant collaboration between clinicians
and fundamental researchers, integration of profes-
sionals from various medical disciplines in a translational
research project (such as pathologists, radiologists, etc.)
or, to a lesser extent, collaboration between different
institutions, particularly concerning rare or childhood
cancers. The collaboration between clinicians and funda-
mental researchers was the most often cited. Participants
who mentioned this type of collaboration argued that
clinicians tend to be more aware about patients’ issues
and hospital constraints, while basic researchers were
said to be more realistic regarding the issue of a project.
One participant summarised:
“Sometimes people who do fundamental research, it is
good, they have ideas, but eventually, they have no
idea about what is a patient, or the same difficulties
[we encounter as clinicians]. And I think that the
clinician’s perspective can make research more
practical, more applied, closer to the issues. On the
contrary, those who carry out fundamental research,
because they don’t have this commitment towards the
patient, are maybe more reasonable regarding what is
possible and not possible, more practical in the
delays of application […]. Or on the contrary more
unreasonable and follow implausible paths that
sometimes lead to nothing, sometimes there are good
ideas that clinicians have not thought of as they keep
their nose to the grindstone.” (Clinician-research,
university hospital, 16 years of experience in cancer
research)
Views of researchers on evaluation of translational cancer
research and indicators (qualitative study)
Existing evaluation systems reward translational research
less favourably
Several researchers (n = 5) felt that the indicators or
evaluation systems currently in place rewarded transla-
tional research less favourably compared with other
types of research. Participants perceived that basic or
fundamental research was seen as more ‘intellectual’, and
therefore of higher value.
A commonly cited example of this bias was the publica-
tion of the results of translational research in prestigious or
high-impact factor journals. The impact factor is an indica-
tor of journal visibility that is based on the ratio of the
number of citations to the number of citeable items of a
journal. Participants mentioned that results of translational
research tend to be published in journals with a lower im-
pact factor than results of fundamental/basic research. One
participant argued that there is not yet a real scientific sup-
port for good or very good translational studies. Another
researcher argued that multidisciplinarity is less well evalu-
ated than mono-thematic research.
As a consequence, physicians and researchers had
fewer incentives to develop translational research pro-
jects, as they were seen as ‘less profitable’ or even ‘risky’
for their career, according to participants. One re-
searcher explained that
“We expect translational research to have much more
impact on treatments and patients care, all medical
aspects that fundamental research… OK there can be
a researcher that spends a lot of time, even all his life,
researching on things that will never be applied.
Translational research is applied research. Which
means there are specific evaluation criterions to this
applied research. In particular the impact in terms of
health that this translational research should have.”
(Clinician-researcher, comprehensive cancer centre,
25 years of experience in cancer research)
Classical indicators are acceptable but not sufficient
Opinions were divided about the utility of existing indi-
cators and evaluation systems, with some participants
positive to those systems and others opposed. The exist-
ing systems we refer to are those routinely used to assess
the performance of researchers and mainly based on
bibliometric indicators such as the number of publica-
tions or impact factor. The most commonly stated opin-
ions on those indicators can be summarised as, “existing
indicators are acceptable but not sufficient to measure
biomedical research/translational research” and “existing
indicators are not adapted to measure biomedical trans-
lational research”.
The impact factor was the indicator that attracted most
critics from participants. One participant felt that it was
detrimental to some disciplines where scientific articles
are not generally published in high impact factor journals.
Two participants noted that negative results are less likely
to be published in high impact factor journals:
“Sometimes a translational research project is a project
that does not confirm a data. […] We talked a lot about
MET for head and neck cancer, we wanted to explore
this marker and see if we could offer treatment against
this oncogene. […] We came to the conclusion that there
was no METabnormality and it was not interesting to
develop clinical strategies for that. We had a lot of
trouble publishing those data because they were
negative.” (Engineer, comprehensive cancer centre,
16 years of experience in cancer research)
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Other participants (n = 5) mentioned research discov-
eries that either had a significant impact on patient care
but were not published in prestigious journals or, on the
contrary, had very favourable bibliometric indicators but
a very limited impact on patient health or that never
even had any clinical application. One participant argued
that publishing in high impact factor journals was a
waste of time, as it required adding an important num-
ber of pointless data. Therefore, publishing in low im-
pact factor journals was a chosen strategy and, thus, the
impact factor an inadequate measure of the quality of
research:
“The only difference between a journal with a high
impact factor and a journal with an average impact
factor is the quantity of data that you add to strengthen
you hypothesis. But if your hypothesis is strong with a
small number of figures, you don’t need to spend two
additional years on the same hypothesis.” (Clinician-
researcher, comprehensive cancer centre, 7 years of
experience in cancer research)
Participants did not mention whether publishing in
open access journals made any difference. Patent count
was also criticised. According to two researchers, a pa-
tent only measured a discovery, but a discovery may
have no impact or never be translated into applications.
A participant argued that patent count could hinder col-
laboration between institutions and researchers, and an-
other that patentability is less important in translational
research than in basic research.
“This indicator [patent count] is pretty good because it
measures innovation and clinical applications. But it
has negative consequences because it can discourage
collaboration. It can incite researchers to keep their
biological material and not share it.” (Pharmacologist,
research agency, 26 years of experience in cancer
research)
Finally, publication count was mentioned as pushing
researchers to move on to another subject rather than
ensuring translation of results into applications and cit-
ation count was seen as an indicator detrimental to
some disciplines.
Measuring translational research in terms of clinical
applications or patient outcomes
Many participants (n = 15) stated that translational re-
search should ideally be evaluated in terms of applica-
tions produced, changes in clinical practice or patient
benefits.
The applications mentioned by participants included
clinical studies generated as a result of translational
findings or to validate those findings, bioinformatics
tools created, valid biomarkers developed, databases gen-
erated, patents, translation of research findings into
treatment protocols or changes in clinical practice, or re-
duction in waiting time to obtain results. One researcher
suggested using indicators specific to translational re-
search protocols (such as the number of patients
included) as means to evaluate global translational activity.
However, one clinician-researcher warned against the sole
count of biomarkers as some developed biomarkers may
prove invalid and their development could lead to a loss
of opportunity for patients participating in subsequent
clinical trials testing this biomarker.
“Let’s take the example of ERCC1, which produced two
‘New England Journal of Medicine’, one therapeutic
trial and eventually had not clinical application. In
your criteria, it comes off at the top of the list,
there is a patent on it… it ticks all the boxes. But
there was no clinical application; it is something
that was dropped. […] In practice not only it has not
been developed, but on top of that there has been
potentially a loss of chance since we used a biomarker
that was retrospectively invalidated.” (Clinician,
comprehensive cancer centre, 9 years of experience in
cancer research)
Most participants argued that translational research
should ideally be measured in terms of patient benefits.
The exact definition of what constituted patient benefits
was not specified and, when specified, could differ be-
tween participants. Survival of the patient, but also
shortening the treatment duration, diminution of doses,
and less side-effects were mentioned as possible clinical
results to be included. One clinician involved in paediat-
ric research mentioned that, for some tumours, the
survival rate is 90%. However, the issue of long-term
toxicities in adult life was an issue of growing import-
ance. Finally, one participant stated the diminution of
treatment costs for healthcare systems as another proxy
on which to evaluate the success of translational
research.
We compiled all suggestions of measure by partici-
pants and the corresponding indicators that could be
used in Table 2. We added those indicators to the Delphi
survey if the definition was clear enough.
Selection of indicators (survey)
First round survey
In the first round, we presented 60 indicators to a panel
of 35 participants. Table 3 shows the rating of each indi-
cator by participants. Forty-two indicators were ex-
cluded, 12 were submitted to a second round, and six
were included in the final set without being submitted to
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a second round. The six indicators included at the end
of the first round were number of clinical trials, percent-
age of patients included in a clinical trial, number of
peer-reviewed publications, number of citations, number
of public-private partnerships, and impact factor. They
were included in the final set without being submitted to
a second round because they received an unusually high
rating for feasibility and validity (≥75%).
Table 2 Suggestions of indicators by participants of the qualitative study
Suggestion or comment by participant Possible indicator (according to author) Authors’ comments
“Collaboration between biologists and
epidemiologists is important and should
be measured in terms of outputs, such
as joint papers”
Number of publications co-authored by an
epidemiologist and a biologist
This is the only indicator of multidisciplinarity
proposed by a participant; however, it is very
specific to research in molecular epidemiology
No similar indicator has been created;
indicator added to the Delphi survey
“One interesting indicator would be the
number of patients in a clinical trial
benefiting from a biomarker identification”
Number of patients included in a clinical trial
with a biomarker identification
That indicator would be studied by a survey
of cancer centres; indicator added to the
Delphi survey
“The point of translational research is to
transfer to clinical practice. So it is supposed
to generate clinical studies. Ideally it
[an evaluation measure] would be how
many positive studies had been generated”
Number of hypotheses generated Literature suggests one indicator of ‘number
of hypotheses generated’ [6], but no
methodology is proposed; indicator added
to the Delphi survey
“A good indicator of translational research
would be its capacity to generate hypothesis
to test in the clinic. […] So the protocols of
clinical validation that have been generated”
“We should ensure whether the tools
developed are effective enough to process
data the correct way”
Measures of effectiveness of developed tools The participant clearly specified that it was an
indicator specific to their field (bioinformatics)
and not applicable to whole translational
research; not added to the questionnaire due
to lack of clear definition
“The primary aim [of translational research]
would be to adapt technologies to the
general population. So it should be
evaluated on this aspect”
Use of developed technologies in practice No existing indicator; not added to the
questionnaire due to lack of clear definition
“ Developing a biomarker in translational
research will help to select patients that will
benefit from a treatment, that is a real
proxy of translational research efficacy”
Number of biomarkers developed Literature suggests one indicator of ‘number
of biomarkers identified’ [6], but no
methodology is proposed; indicator already
part of the Delphi survey
“What should be measured, for translational
research, is the benefit for the patient.
Not the final benefit […] but the interim
benefit, such as biomarkers developed”
“The ideal for translational research, it that
it modifies patient care. So that can be a
long-term objective, but […] if there are
interim step”
“Ideally, a translational study should lead to
an application, which means, from clinical
to basic research, to a fundamental research
project, and in the opposite direction, to a
clinical application, such as a clinical trial,
the validation of a biomarker, or an
imaging study”
“[translational research should be evaluated]
in terms of publications and implementations
in the clinics. […] Also guidelines”
Clinical guidelines generated There are two existing indicators measuring
the transfer of research in clinical guidelines:
number of clinical guidelines generated and
citation of research in clinical guidelines;
indicators already part of the Delphi survey
“The development of database is also an
important structural factor… an indicator”
Number of databases created Literature suggests one indicator of ‘number
of databases created’ [6], but no methodology
is proposed; indicator added to the Delphi
survey
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Table 3 Rating and selection of indicators by participants to the Delphi survey
Round 1 Round 2
Indicator Feasibility Validity Status Validity Status
Number of clinical trials 81% 84% Included – Included
Percentage of patients included in a clinical trial 77% 81% Included – Included
Number of peer-reviewed publications 95% 81% Included – Included
Number of citations 88% 85% Included – Included
Number of public-private partnerships 75% 78% Included – Included
Impact factor 96% 76% Included – Included
Institutional h-index 92% 73% Second round 83% Included
Number of publications co-authored with another organisation 92% 72% Second round 76% Included
Mean number of citations per article 91% 69% Second round 66% Included
Number of highly cited publications 78% 67% Second round 69% Included
Number of publications in top-ranked journals 85% 65% Second round 69% Included
z-index 83% 71% Second round 69% Included
Number of publications with international collaboration 92% 67% Second round 85% Included
Number of biomarkers identified 33% 52% Modified 58% To be discussed
Citation of research in clinical guidelines 71% 71% Second round 62% To be discussed
Generation of clinical guidelines 74% 67% Second round 54% To be discussed
Citation of research in public health guidelines 60% 58% Modified 50% To be discussed
Number of patents 88% 65% Second round 38% Excluded
Number of patients in a clinical trial with a biomarker identification 56% 58% Excluded – –
Number of biological samples collected 69% 50% Excluded – –
Number of biological samples transmitted 42% 34% Excluded – –
Number of hypotheses generated 46% 46% Excluded – –
Number of diagnostic tests created 50% 45% Excluded – –
Number of database generated 50% 38% Excluded – –
Number of research projects ongoing 57% 29% Excluded – –
Number of assays developed 0% 0% Excluded – –
Number of visits to EXPASY server 75% 0% Excluded – –
Clinicians’ awareness of research results 22% 36% Excluded – –
Changes in clinical practices 21% 43% Excluded – –
Contribution to reports informing policy makers 58% 35% Excluded – –
Number of presentations at key selected conferences 60% 56% Excluded – –
Citation in medical education books 42% 48% Excluded – –
Number of conferences held 71% 38% Excluded – –
Citation of research in the media 41% 28% Excluded – –
Number of papers co-authored with the industry 74% 61% Excluded –
Citation of research in patents 79% 58% Excluded – –
Patent h-index 52% 52% Excluded – –
Number of patent citations 73% 48% Excluded – –
Number of spin-off companies created 86% 43% Excluded – –
Partnership-ability index 82% 50% Excluded – –
Dependence degree (d-index) 67% 50% Excluded – –
Proportion of long-distance collaborative publications 43% 0% Excluded – –
Number of publications co-authored by an epidemiologist and biologist 52% 41% Excluded – –
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Most indicators (n = 51) received comments from
participants. Those comments were used to modify
the definition or methodology of those indicators.
Nine indicators received no comments. As those indi-
cators were the ones that received low ratings for
feasibility and validity, they were discarded without
further action. A selection of the most common or
most striking comments is presented in Additional
file 3. The indicator that received comments from
most participants was ‘number of biomarkers identi-
fied’ (commented by 16 participants). Following those
comments, we modified its definition into ‘number of
valid biomarkers identified by the institution and pub-
lished in a peer-review journal’. Another indicator
that received many comments was the ‘number of ci-
tations in public health guidelines’ for which many
participants asked for clarifications about the method-
ology and definition.
Second round survey
In the second round, we presented 12 indicators for rat-
ing. Seven of them were included, one was excluded and
four were presented for discussion. The seven indicators
included were h-index (for institution), number of publi-
cations co-authored with another institution, mean
number of citations per article, number of publications
in top-ranked journals, z-index (an indicator combining
the number of publications and the impact factor of
those publications), and number of publications with
international collaboration.
Physical meeting
During a consortium meeting, we organised a session
dedicated to indicators. This session was attended by 26
experts, 14 of whom had participated in the survey and
the remaining 12 were representatives of participating
institutions. The discussion was focused on four indica-
tors: number of valid biomarkers identified by the insti-
tution and published in a peer-review journal, number
of citations in clinical guidelines, number of citation in
public health guidelines, and number of clinical guide-
lines authored. The discussion was focused on those four
indicators since the methodology and definition of these
received the most comments and questions in both
rounds of the survey. This meeting was moderated by
FT and MS. One of the most important points of discus-
sion concerned the inclusion of clinical guidelines for
the indicator ‘number of citations in clinical guidelines’.
As a conclusion to this discussion, the expert panel
agreed on the necessity to define the objective criter-
ion for the inclusion of clinical guidelines based on
their quality. At the end of this meeting, we included
the four indicators in the set, with the suggestions of
participants. In total, 17 indicators were included in
the final set. The final list of selected indicators is de-
tailed in Table 4.
Table 3 Rating and selection of indicators by participants to the Delphi survey (Continued)
Age-weighted citation rate 71% 33% Excluded – –
b-index 83% 43% Excluded – –
Central index 60% 50% Excluded – –
CH-index 50% 0% Excluded – –
Crown indicator 33% 0% Excluded – –
e-index 80% 50% Excluded – –
g-index 100% 0% Excluded – –
Hg-index 33% 0% Excluded – –
j-index 75% 33% Excluded – –
m-index 50% 25% Excluded – –
m-quotient 67% 60% Excluded – –
Mean normalised citation score 50% 33% Excluded – –
Q2 index 25% 0% Excluded – –
r-index 83% 33% Excluded – –
SP-index 100% 50% Excluded – –
w-index 71% 33% Excluded – –
x-index 50% 0% Excluded – –
Percentage of participants rating the indicator in the top tertile (7–9/9). Included: the indicator is included in the final set. Excluded: the indicator is excluded from
the selection. Second round: the indicator is submitted to the second round of rating. Modified: The indicator is submitted to the second round of rating with
significant changes in the definition and/or methodology following the respondents’ comments. To be discussed: the methodology of the indicator will be
discussed in the expert meeting.
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Table 4 Selected indicators
Indicator Definition Type of
indicator
Why it measures the impact of
translational research
Number of clinical trial Number of clinical trials active in a
cancer centre in a year
Process Those indicators measures how research
and care are integrated into a hospital
Percentage of patients included in a
clinical trial
Ratio of the number of patients
included in a clinical trial to the
total number of patients
Process
Number of peer-reviewed publications Number of peer-reviewed publications
authored by the institution
Output Peer-reviewed publications play a
fundamental role in the circulation
and exploitation of knowledge
Number of citations Number of citations of the published
articles of an institution received
within a time span
Output It measures how an article has influenced
other scientists and its impact on the
advancement of knowledge
Impact factor The ratio of the number of citations
to the number of citable items of a
journal
Output This indicator measures the visibility of
the production of a research institute
Institutional h-index Indicator that combines the number
of articles produced by research units
and their number of citations
Output As this indicator combines metrics of
quantity and visibility, it measures the
possible influence of the entire
production of a research institute
Number of public-private partnerships Number of partnerships between an
academic research centre and the
industry
Process Public-private partnerships facilitate the
translation of research finding into
clinical applications
Mean number of citations per article A ratio of the number of citations
received by an institution to their
number of publications
Output This indicator allows a comparison of
the potential influence of an institution
adjusted for their age
Number of highly cited publications Number of published articles with a
citation count above a certain
threshold
Output This indicator potentially measures the
number of articles that had a high
impact in the research community
Number of publications in top-ranked
journals
Number of publications in journals
with the highest impact factor in the
discipline
Output This indicator allows adjustment for
differences in citation practices between
disciplines
z-index An indicator combining the number
of publications of an institution and
the impact factor of those publications
Output As this indicator combines metrics of
quantity and visibility, it measures the
possible influence of the entire
production of a research institute
Number of publications co-authored
with another organisation
Number of publications co-authored
by researchers affiliated to another
research institution
Output Cooperation benefits research by
bringing new ideas and methods
and helping to reach comprehensive
expertise. In cancer research,
collaboration between institutions is
particularly crucial for research on rare
cancers where it can be challenging
to include enough patients. Those
indicators measure the proportion of
research performed during a collaboration
Number of publications with international
collaboration
Number of publications co-authored
by researchers affiliated to a research
institution in another country
Output
Number of biomarkers identified Number of valid biomarkers identified
by the research institution and
published in a peer-review journal.
Outcome Biomarkers play a fundamental role in
developing personalised treatments and
possibly improving patient outcomes
Generation of clinical guidelines Number of clinical guidelines
authored by the institution
Outcome Clinical guidelines facilitate the adoption
of research findings into practices and
aim to improve care quality Those
indicators measure the possible influence
of research on the improvement of
clinical practices
Citation of research in clinical guidelines Number of articles cited in clinical
guidelines
Outcome
Citation of research in public health
guidelines
Number of articles cited in public
health guidelines
Outcome This indicator measures the possible
influence of research findings on public
policies (e.g. cancer screening)
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Discussion
Main findings
The aim of the present study was to explore the defini-
tions and issues of translational cancer research accord-
ing to its researchers, to explore their views on the
evaluation of translational cancer research, and to select
indicators measuring the output and outcome of transla-
tional cancer research. We found many divergences in
the exact scope and limits of translational research
despite a common definition. Almost all researchers
indicated the necessity of multidisciplinarity and collab-
oration, particularly between physicians and basic re-
searchers, for the success of translational cancer
research. Participants had various opinions about the in-
dicators and evaluation systems currently in place; how-
ever, most called for the introduction of indicators and
an evaluation system more focused on benefits to pa-
tients and applications produced.
Most participants defined translational research as a
process of translation of basic findings into clinical ap-
plications, but very few included the process of translat-
ing research into clinical practice. The first process
(from basic science to clinical research) has been defined
as ‘T1’, while the second has been defined as ‘T2’ [17].
This study confirms that the T2 definition of transla-
tional research is overlooked in favour of the T1 def-
inition. Woolf [18] argues that, as most new drugs
only marginally improve efficacy, T2 research has a
bigger potential for health and the lack of interest in
this part of translational research is problematic for
public health.
Although the participants of the qualitative study
expressed a wish for the introduction of new indicators
measuring the longer-term impact of translational re-
search on patients, the results of the Delphi survey differ,
with ‘traditional’ indicators (such as number of publica-
tions, number of citations and h-index) having the
highest ratings and indicators of health service impact
(such as citation in clinical guidelines or number of bio-
markers identified) having lower ratings. This is possibly
due to the fact that those indicators are not routinely
used in the evaluation systems currently in place and
hence the less clear methodology and lack of familiarity
of researchers with these; this might be linked to the
Delphi process itself where the necessity for consensus
tends not to favour innovative ideas.
There was a significant focus on biomarkers in both
studies. On the one hand, many participants of the
qualitative study mentioned the identification of bio-
markers as a proxy for the success of translational
cancer research; on the other hand, the proposed indica-
tor ‘number of biomarkers identified’ received the most
comments during the Delphi survey. Biomarkers are de-
fined by the National Cancer Institute as “a biological
molecule found in blood, other fluids, or tissues that is a
sign of a normal or abnormal process or of a condition or
disease” [19]. Biomarkers can have many uses such as
estimating the risk of a disease, screening for primary
cancers, distinguishing a benign from a malignant
tumour, determining prognosis and prediction for pa-
tients who have been diagnosed with a cancer, and
monitoring disease status [18]. Biomarkers play a sig-
nificant role in developing personalised treatments
[20,21] and possibly improving patient outcomes [22].
Therefore, measuring the development of valid bio-
markers seems an interesting indicator to measure
the impact of translational cancer research. Although
suggested once in the literature [6], this indicator has
not been tested or used.
Strengths and limitations of the study (internal validity)
The present study used a mix of qualitative and quanti-
tative methods to investigate the views of researchers on
the evaluation of translational cancer research outcomes.
We believe that both methods are complementary and
their combined use can enhance results [23]. A further
strength is the inclusion of participants from a broad
range of specialties and backgrounds in both the
qualitative study and the Delphi survey. Participants
in both studies were involved in various areas of
translational research, such as pre-clinical research,
phase one studies, epidemiological research, drug de-
velopment, and administration/management, and have
diplomas in disciplines as diverse as biology, informa-
tion science, physics, chemistry, pharmacology or
medicine. They also represented most of the institu-
tions in the research consortium. It has been argued
that having a heterogeneous sample of participants
enhances generalisation in a qualitative study [24] as
well as the validity of a Delphi survey [13].
Our study also has limitations. There was a low par-
ticipation rate, both in the first round and second round
of the Delphi survey. Indeed, keeping adhesion of panel
members is one issue of the Delphi procedure [13].
However, the heterogeneity of the sample, both in terms
of background, occupation and institutions of affiliation,
reduced the effect of this bias, as explained earlier. Out
of the 267 researchers invited for the Delphi survey, only
35 participated in the first round. This figure can be ex-
plained by the length of the questionnaire and by the
fact there was no pre-selection of participants based on
their willingness to be included in the survey. Although
it is a low take-up rate, a panel of 35 participants is suffi-
cient for a Delphi survey [13]. The participation rate
dropped between the first and second Delphi round.
The Delphi can be a long process, participants must
complete the questionnaire despite their busy schedules
and non-respondents must be contacted. However,
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despite reminders, some participants did not respond.
Although some of the panellists failed to participate in
all the steps of the Delphi survey (suggesting some de-
gree of weariness with the process), the participation
rate was within the range of previous studies, and in-
complete participation does not undermine the validity
of the results.
Although our study had a focus on developing indica-
tors measuring patient benefits, the final list contains
only a relatively small number of these since most of the
indicators of health service impact and patient benefits
found in the literature either had little or no method-
ology provided or received a low rating for feasibility or
validity. Some of those indicators could be interesting to
develop for a case study analysing the impact of the re-
search of a small number of cancer research institutions.
However, they are not suited for a large-scale bibliomet-
ric study.
Strengths and limitations of our study in relation to other
studies (external validity)
The divergences in the definitions of translational re-
search by the stakeholders involved have been previ-
ously highlighted in the literature [25]. However, the
necessity for collaboration between basic researchers
and clinicians has already been underlined. Lord et al.
[26] and de Bono [27] argue that cancer biologists do
not have the same understanding of what constitutes
a feasible target or a thorough understanding of clin-
ical issues as clinicians, but nevertheless should have
a crucial role in the design and analysis of clinical tri-
als. Pober et al. [28] argue that, traditionally, the re-
sponsibility for making the connection between
laboratory and clinic has fallen on the clinicians-
researchers. However, due to difficulties in recruiting
and maintaining statutory physicians-researchers with
both clinical and basic science training, creating transla-
tional research teams with clinicians and laboratory-based
investigators is a viable solution.
In the qualitative study, many researchers argued that
translational research does not get published in high
impact factor journals, and therefore bibliometric indica-
tors do not favour translational cancer research. This
opinion seems to be corroborated by a scientometric
study [29] which examined trends in publications of
translational research. This article found that amongst
the first 20 journals in which most translational results
are published, only four had an impact factor above 5
and only one an impact factor above 10. However, that
article was not specific to cancer research and did not
compare translational research publications with basic
research publications.
Compared with the study from Rajan et al. [7], our
study holds significant differences. Firstly, the Excellence
Designation System proposed relies on peer review by
experts, which requires organisation and participant in-
put, while the set of indicators that we have devel-
oped can be measured using bibliometric data with
minimal effort from participants. We believe both ap-
proaches are complementary. Indeed, it has been ar-
gued that both peer-review and bibliometrics can
offer different and complementary methods to evalu-
ate research [30]. Finally, the Excellence Designation
System evaluates the quality of translational cancer
research with a focus mostly on structure and
process, while the set of indicators we propose is fo-
cused on research output and outcome.
Policy implications
This study has enabled us to explore the scope and is-
sues relevant to the evaluation of the outcome of trans-
lational research and to select indicators to measure it.
However, to be effective, indicators need to be accepted
by the stakeholders who will be evaluated. An important
added value from our study is that the feedback from
the participants in both the qualitative study and the
modified Delphi survey has considerably helped us refine
the methodology and definition of the indicators se-
lected. However, some problems remain, mainly with the
lack of consensus with the exact scope of translational
research. The disagreements between researchers re-
garding the limits and scope of translational research
could pose a problem when designing an evaluation sys-
tem that would be acceptable to most. For example,
some indicators suggested by participants, such as the
number of fundamental hypothesis generated, might be
rejected by those for whom translational research is a
one-way process only from the bench to the bedside.
Another issue was the many divergences and discussions
concerning some indicators that are not routinely used.
Exploring the views of researchers on those indicators
once they have been tested and used would be very
informing.
Conclusion
This study has enabled us to receive input from actors
in translational cancer research on the important issues
related to the evaluation of the selected indicators, and
to clarify their methodology. We selected a total of 17
indicators, including several new ones measuring the im-
pact of research in terms of health service and patient
outcomes. However, some indicators proposed are not
routinely used and many researchers are not familiar
with these. Testing this set of indicators will provide a
more in-depth analysis on their feasibility and validity. A
scientometric study of cancer centres using those indica-
tors is warranted.
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